

JESSICA CHUBAK

Curriculum vitae

BIOGRAPHICAL INFORMATION

Jessica Chubak
Group Health Research Institute
1730 Minor Avenue, Suite 1600
Seattle, WA 98101-1448
Phone: 206-287-2556
Fax: 206-287-2871
E-mail: chubak.j@ghc.org

EDUCATION

Bachelor of Arts in Molecular Biology, *summa cum laude*, May 2000
Pomona College, Claremont, California

Master of Bioethics and Health Law, awarded with distinction, March 2002
University of Otago, Dunedin, New Zealand

Doctor of Philosophy in Epidemiology, August 2007
University of Washington, Seattle, Washington

LICENSURE

Not applicable

PROFESSIONAL POSITIONS

Current position

Associate Scientific Investigator, 2013 – present
Group Health Research Institute, Seattle, Washington

Affiliate Associate Professor, 2014 – present
Department of Epidemiology, University of Washington School of Public Health and Community
Medicine, Seattle, Washington

Past positions

Assistant Scientific Investigator, 2007 – 2013
Group Health Research Institute, Seattle, Washington

Affiliate Assistant Professor, 2008 – present
Department of Epidemiology, University of Washington School of Public Health and Community
Medicine, Seattle, Washington

Bioethics Tutor (Section Lecturer), 2001 – 2002
University of Otago Medical School, Dunedin, New Zealand

Research Assistant, 2002 – 2006
Fred Hutchinson Cancer Research Center, Seattle, Washington

Epidemiologic Methods Teaching Assistant, 2006 – 2007

University of Washington School of Public Health and Community Medicine, Seattle, Washington

HONORS, AWARDS, SCHOLARSHIPS

Tileston Physics 1 Prize, top student in introductory physics course, Pomona College, 1997
 Pomona College Scholar, 1997 – 1999
 Phi Beta Kappa, Pomona College, 1999
 Phi Beta Kappa Award, awarded for quality of scholarship and promise of future distinction, 2000
Summa cum laude, Pomona College, 2000
 Rena Gurley Archibald High Scholarship Prize, awarded to college's highest ranked graduate, 2000
 Fulbright Graduate Student Award to New Zealand, 2000 – 2002
 Master's degree awarded with distinction, 2001
 NIH Cancer Epidemiology and Biostatistics Training Program pre-doctoral trainee, 2003 – 2006
 Presenter, Student Workshop, Society for Epidemiologic Research, Toronto, Canada, 2005
 International Society for Pharmacoepidemiology, travel scholarship, 2006
 American Society of Preventive Oncology, abstract among top 16 at annual meeting, 2009
 Cancer Research Network (CRN) Scholars Program participant, 2009 – 2011
 American Society of Preventive Oncology, honorable mention for poster, annual meeting, 2012
 International Cancer Screening Network, travel scholarship, 2012
 Participant and presenter, National Cancer Institute, Division of Cancer Control and Prevention, New
 Grantee Workshop, 2014.

PROFESSIONAL ACTIVITIES

Committees

Student Health Advisory Committee, Pomona College, 1996 – 1997
 Epidemiology Seminar Planning Committee, University of Washington, 2002 – 2003
 Co-director & co-founder, Forum on Science Ethics and Policy (FOSEP), University of Washington,
 2004 – 2007
 Graduate Process Advisory Committee, University of Washington, 2004 – 2006
 Research Ethics Education Oversight Committee, Fred Hutchinson Cancer Research Center, 2003 –
 2007
 Member, Survivorship Task Force, Washington CARES About Cancer Partnership, 2008 – present
 Member, Postdoctoral Fellow Search Committee, Group Health Center for Health Studies, 2008
 Member, Faculty Retreat Planning Committee, Group Health Center for Health Studies, 2008
 Member, Scientific Policy Committee, Group Health Research Institute, 2009 – 2013
 Co-chair, Scientific Policy Committee, Group Health Research Institute, 2010 – 2011
 Member, Strategic Planning Steering Committee, Group Health Research Institute, 2011
 Co-chair, Scientific Policy Committee, Group Health Research Institute, 2012 – 2013
 Member, Technical Specialist Hiring Committee, Group Health Research Institute, 2013
 Member, American Society of Preventive Oncology Junior Members Organizing Committee, 2013

Study section and grant reviews

Reviewer, Native Elder Research / Resource Center for Minority Aging Research (NERC/RCMAR)
 Native Investigator Program, mock NIH review section, University of Washington, 2008
 Reviewer, Group Health Partnership for Innovation, 2008, 2010
 Reviewer, Cancer Research Network Pilot Projects, 2008 – 2009
 Reviewer, Institute of Translational Health Sciences Community/Practice-Based Research Activity
 Funding, 2010

Reviewer, Cancer Research Network Scholars Program, 2013
 Reviewer, Patient Centered Outcomes Research Institute, PCORI Cycle II, Comparative Effectiveness Research Panel A, 2013
 Reviewer, Emerging Leaders In Science & Society Fellowship, American Association for the Advancement of Science, 2014
 Reviewer, Diabetes UK, 2014

Manuscript reviewer

Ad hoc reviewer, Pharmacoepidemiology and Drug Safety, 2008 – present
 Ad hoc reviewer, Cancer Causes and Control, 2008 – present
 Ad hoc reviewer, Cancer Epidemiology Biomarkers & Prevention, 2008 – present
 Ad hoc reviewer, American Journal of Epidemiology, 2008 – present
 Ad hoc reviewer, Breast Cancer Research and Treatment, 2011 – present
 Ad hoc reviewer, European Journal of Public Health, 2011 – present
 Ad hoc reviewer, Medical Care, 2011 – present
 Ad hoc reviewer, Cancer Epidemiology, 2011 – present
 Ad hoc reviewer, Journal of Oncology Practice, 2012 – present
 Ad hoc reviewer, European Journal of Gastroenterology & Hepatology, 2012 – present
 Ad hoc reviewer, Journal of Clinical Epidemiology, 2012 – present
 Ad hoc reviewer, Health Services Research, 2013 – present
 Ad hoc reviewer, Journal of the National Cancer Institute, 2014 – present
 Ad hoc reviewer, Annals of Epidemiology, 2014 – present
 Ad hoc reviewer, Epidemiologic Methods, 2014 – present
 Ad hoc reviewer, British Journal of Cancer, 2014 – present
 Ad hoc reviewer, JAMA Oncology, 2015 – present

Membership in professional organizations

American Society of Preventive Oncology, 2008 – present
 Society for Epidemiologic Research, 2009 – present
 International Society for Pharmacoepidemiology, 2011

BIBLIOGRAPHY

Peer-reviewed research articles

1. Tworoger SS, **Chubak J**, Aiello EJ, Ulrich CM, Atkinson C, Potter JD, Yasui Y, Stapleton PL, Lampe JW, Farin FM, Stanczyk FZ, McTiernan A. Association of *CYP17*, *CYP19*, *CYP11B1*, and *COMT* polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. *Cancer Epidemiol Biomarkers Prev*. 2004 Jan;13(1):94-101.
2. Tworoger SS, **Chubak J**, Aiello EJ, Yasui Y, Ulrich CM, Farin FM, Stapleton PL, Irwin ML, Potter JD, Schwartz RS, McTiernan A. The effect of CYP19 and COMT polymorphisms on exercise-induced fat loss in postmenopausal women. *Obes Res*. 2004 Jun;12(6):972-81.
3. McTiernan A, Tworoger SS, Rajan KB, Yasui Y, Sorenson B, Ulrich CM, **Chubak J**, Stanczyk FZ, Bowen D, Irwin ML, Rudolph RE, Potter JD, and Schwartz RS. Effect of exercise on serum androgens in postmenopausal women: A 12-Month randomized clinical trial. *Cancer Epidemiol Biomarkers Prev*. 2004 Jul;13(7):1099-1105.

4. **Chubak J**, Tworoger SS, Aiello EJ, Yasui Y, Ulrich CM, Stanczyk FZ, McTiernan A. Associations between reproductive and menstrual factors and postmenopausal sex hormone concentrations. *Cancer Epidemiol Biomarkers Prev.* 2004 Aug;13(8):1296-1301.
5. **Chubak J**, Tworoger SS, Yasui Y, Ulrich CM, Stanczyk FZ, McTiernan A. Associations between reproductive and menstrual factors and postmenopausal androgen concentrations. *Journal of Women's Health.* 2005 Nov;14(8):704-712.
6. Mohanka M, Heckbert SR, Yasui Y, Sorensen B, **Chubak J**, Tworoger SS, Ulrich CM, McTiernan A. Serum lipoproteins in overweight/ obese postmenopausal women: 1-year exercise clinical trial. *Medicine & Science in Sports & Exercise.* 2006 Feb;38(2):231-9.
7. **Chubak J**, Ulrich CM, Tworoger SS, Sorensen B, Yasui Y, Irwin ML, Stanczyk FZ, Potter JD, McTiernan A. Effect of exercise on bone mineral density and lean mass in postmenopausal women. *Medicine & Science in Sports & Exercise.* 2006 Jul;38(7):1236-1244.
8. **Chubak J**, McTiernan A, Sorensen B, Wener MH, Yasui Y, Velasquez M, Wood B, Rajan KB, Wetmore CM, Potter JD, Ulrich CM. Moderate-intensity exercise reduces the incidence of colds among postmenopausal women – results from a randomized trial. *American Journal of Medicine.* 2006 Nov;119(11):937-942.
9. Tworoger S, Sorensen B, **Chubak J**, Irwin M, Stanczyk F, Ulrich C, Potter J, McTiernan A. Effect of a 12-month randomized clinical trial of exercise on serum prolactin concentrations in postmenopausal women. *Cancer Epidemiol Biomarkers Prev.* 2007 May;16(5):895-899.
10. Rhew I, Yasui Y, Sorensen B, Ulrich CM, Neuhouser M, Potter JD, Tworoger SS, **Chubak J**, Bowen DJ, McTiernan A. Minimal effects of an exercise intervention trial on self-reported health behaviors in obese post-menopausal women. *Contemporary Clinical Trials.* 2007 Jul;28(4):472-481.
11. **Chubak J**, Doherty JA, Cushing-Haugen KL, Voigt LF, Saltzman BS, Hill DA, Beresford SAA, Weiss NS. Endometrial cancer risk in estrogen users after switching to estrogen-progestin therapy. *Cancer Causes Control.* 2007 Nov;18(9):1001-1007.
12. **Chubak J**, Buist DSM, Boudreau DM, Rossing M, Lumley T, Weiss NS. Breast cancer recurrence risk in relation to antidepressant use after diagnosis. *Breast Cancer Research and Treatment.* 2008;112:123-132.
13. Hawkins V, Foster-Schubert K, **Chubak J**, Sorensen B, Ulrich CM, Stanczyk FZ, Plymate S, Stanford J, White E, Potter JD, McTiernan A. Effect of exercise on serum sex hormones in men: a 12-month randomized clinical trial. *Medicine & Science in Sports & Exercise.* 2008 Feb;40(2):223-233.
14. **Chubak J**, Bowles EA, Terry MB, Trentham-Dietz A, Buist DSM. Antidepressant medications and change in mammographic density in postmenopausal women. *Cancer Epidemiol Biomarkers Prev.* 2009 Feb;18(2):676-679.
15. **Chubak J**, Boudreau DM, Rulyak SJ, Mandelson MT. Colorectal cancer risk in relation to use of acid suppressive medications. *Pharmacoepidemiology and Drug Safety.* 2009 Jul;18(7):540-4.
16. Buist DSM, **Chubak J**, Prout M, Yood MU, Bosco JLF, Thwin SS, Gold HT, Owusu C, Field TS, Quinn VP, Wei F, Silliman RA. Referral, receipt, and completion of chemotherapy in patients with early-stage breast cancer older than 65 years and at high risk of breast cancer recurrence. *J Clin Oncol.* 2009 Aug;27(27):4508-4514.
17. **Chubak J**, Boudreau DM, Fishman PA, Elmore JG. Cost of breast-related care in the year following false positive screening mammograms. *Med Care.* 2010 Sep;48(9):815-20.

18. Green BB, Wang CY, Horner K, Catz S, Meenan RT, Vernon SW, Carrell D, **Chubak J**, Ko C, Laing S, Bogart A. Systems of Support to increase colorectal cancer screening and follow-up rates (SOS): design, challenges, and baseline characteristics of the study population. *Contemp Clin Trials*. 2010 Jul;31:589-603.
19. **Chubak J**, Boudreau DM, Rulyak SJ, Mandelson MT. Colorectal cancer risk in relation to antidepressant medication use. *Int J Cancer*. 2011 Jan;128(1):227-32.
20. Liss DT, **Chubak J**, Anderson ML, Saunders KW, Tuzzio L, Reid RJ. Patient-reported care coordination: associations with primary care continuity and specialty care use. *Ann Fam Med*. 2011 Jul-Aug;9(4):323-329.
21. **Chubak J**, Pocobelli G, Weiss NS. Tradeoffs between accuracy measures for electronic healthcare data algorithms for epidemiologic and health services research. *Journal of Clinical Epidemiology*. 2012 Mar;65(3):343-349.
22. **Chubak J**, Tuzzio L, Hsu C, Alfano CM, Rabin B, Hornbrook MC, Spegman A, Von Worley A, Williams A, Nekhlyudov L. Providing care to cancer survivors in integrated healthcare delivery systems: practices, challenges, and research opportunities. *Journal of Oncology Practice*. 2012 May;8(3):184-9.
23. Bowles EJA, Buist DSM, **Chubak J**, Yu O, Johnson J, Chestnut J, Boudreau DM. Endocrine therapy initiation from 2001 through 2008 varies by age of breast cancer diagnosis and tumor size. *Journal of Oncology Practice*. 2012 Mar;8(2):113-120.
24. Green BB, Bogart A, **Chubak J**, Vernon SW, Morales LS, Meenan R, Laing SS, Fuller SF, Ko, C, Wang CY. Nonparticipation in a population-based trial to increase screening rates. *American Journal of Preventive Medicine*. 2012 Apr;42(4):390-7.
25. **Chubak J**, Yu O, Pocobelli G, Lamerato L, Webster J, Prout MN, Ulcickas Yood M, Barlow WE, Buist DSM. Algorithms to identify second breast cancer events using administrative data. *Journal of the National Cancer Institute*. 2012 Jun;104(12):931-40.
26. **Chubak J**, Anderson ML, Saunders KW, Hubbard RA, Tuzzio L, Liss DT, Morales LS, Reid RJ. Predictors of one-year change in patient activation among older adults with diabetes and heart disease. *Journal of the American Geriatrics Society*. 2012 Jul;60(7):1316-21.
27. Bowles EJA, Boudreau DM, **Chubak J**, Yu O, Fujii M, Chestnut J, Buist DSM. Patient-reported discontinuation of endocrine therapy and related side effects among women with early stage breast cancer. *Journal of Oncology Practice*. 2012 Nov;8(6):e149-57.
28. *Pocobelli G, **Chubak J**, Hanson N, Drescher C, Resta R, Urban N, Buist DSM. Prophylactic oophorectomy rates in relation to a guideline update on referral to genetic counseling. *Gynecol Oncol*. 2012 Aug;126(2):229-35.
29. Henderson JA, **Chubak J**, O'Connell J, Ramos MC, Jensen J, Jobe, JB. Design of a randomized controlled trial of a web-based intervention to reduce cardiovascular disease risk factors among remote-dwelling American Indians. *J Prim Prev*. 2012 Aug;33(4):209-222.
30. Nekhlyudov L, Greene SM, **Chubak J**, Rabin B, Tuzzio L, Rolnick S, Field TS. Cancer Research Network: Using Integrated Healthcare Delivery Systems as Platforms for Cancer Survivorship Research. *Journal of Cancer Survivorship*. 2013 Mar;7(1):55-62.
31. Doubeni CA, Weimann S., Adams K, Kamineni A, Buist DM, Ash AS, Rutter CM, Doria-Rose VP, Corely DA, Greenlee RT, **Chubak J**, Williams A, Kross-Desrosiers AR, Johnson E, Webster J, Richert-Boe K, Levin TR, Fletcher RH, Weiss NS. Screening colonoscopy and risk of incident late-

- stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. *Annals of Internal Medicine*. 2013 Mar;158:312-320.
32. Green BB, Wang CY, Anderson ML, **Chubak J**, Meenan RT, Vernon SW, Fuller S. An automated intervention with stepped increases in support to increase uptake of colorectal cancer screening: a randomized trial. *Annals of Internal Medicine*. 2013 Mar;158(5 Pt 1):301-311.
 33. **Chubak J**, Rutter CM, Kamineni A, Johnson EA, Stout NK, Weiss NS, Doria-Rose VP, Doubeni CA, Buist DSM. Measurement in comparative effectiveness research. *American Journal of Preventive Medicine*. 2013 May;44(5):513-519.
 34. *Lowry S, **Chubak J**, Press OW, McKnight B, Weiss NS. Risk of non-Hodgkin lymphoma in relation to tricyclic antidepressant use. *Annals of Epidemiology*. 2013 Jun;23(6):349-354.
 35. Perdue D, **Chubak J**, Dillard D, Bogart A, Buchwald D. A comparison of colorectal cancer screening uptake among average-risk insured American Indian/Alaska Native and white women. *Journal of Health Care for the Poor and Underserved*. 2013 Aug;24(3):1125-35.
 36. Wirtz HS, Buist DSM, Gralow JR, Barlow WE, Gray SL, **Chubak J**, Yu O, Bowles EJA, Fujii M, Boudreau DM. Frequent antibiotic use and second breast cancer events. *Cancer Epidemiol Biomarkers Prev*. 2013 Sep;22(9):1588-99.
 37. **Chubak J**, Boudreau DM, Wirtz HS, McKnight B, Weiss NS. Threats to the validity of non-randomized studies of post-diagnosis exposures on cancer recurrence and survival. *Journal of the National Cancer Institute*. 2013 Oct;105(19):1456-62.
 38. **Chubak J**, Bogart A, Fuller S, Laing SS, Green BB. Uptake and positive predictive value of fecal occult blood tests: a randomized controlled trial. *Prev Med*. 2013 Nov;57(5):671-8.
 39. Wagner E, Aiello Bowles EJ, **Chubak J**, Horner K, Lapham B, Ludman E, McCorkle R, Penfold R, Reid F, Rutter C. Nurse navigators in early cancer care: a randomized, controlled trial. *Journal of Clinical Oncology*. 2014 Jan;32(1):12-8.
 40. Laing SS, Bogart A, **Chubak J**, Fuller S, Green BB. Psychological distress after a positive fecal occult blood test result among members of an integrated delivery system. *Cancer Epidemiol Biomarkers Prev*. 2014 Jan;32(1):154-9.
 41. Carrell D, Halgrim S, Tran D-T, Buist DSM, **Chubak J**, Chapman WW, Savova GK. Using natural language processing to improve efficiency of manual chart abstraction in research: the case of breast cancer recurrence. *American Journal of Epidemiology*. 2014 Mar;179(6):749-58.
 42. Boudreau DM, Yu O, **Chubak J**, Wirtz HS, Bowles EJA, Fujii M, Buist DSM. Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. *Breast Cancer Res Treat*. 2014 Apr;144(2):405-16.
 43. **Chubak J**, Aiello Bowles EJ, Tuzzio L, Ludman E, Rutter CM, Reid RJ, Wagner E. Perspectives of cancer survivors on the role of different healthcare providers in an integrated delivery system. *Journal of Cancer Survivorship: Research and Practice*. 2014 Jun;8(2):229-38.
 44. Tiro JA, Kamineni A, Levin TR, Zheng Y, Schottinger JC, Rutter CM, Corley DA, Skinner CS, **Chubak J**, Doubeni CA, Halm E, Gupta S, Wernli K, Klabunde CK. The colorectal cancer (CRC) screening process in community settings: A conceptual model for the Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) Consortium. *Cancer Epidemiol Biomarkers Prev*. 2014 Jul;23(7):1147-58.

45. Wernli KJ, Hubbard R, Johnson E, **Chubak J**, Kamineni A, Green BB, Rutter CM. Patterns of colorectal cancer screening uptake in newly-eligible men and women. *Cancer Epidemiol Biomarkers Prev.* 2014 Jul;23(7):1230-7.
46. Wang CY, Tapsoba JD, Anderson M, Vernon SW, **Chubak J**, Fuller S, Green B. Time to Screening in the Systems of Support to Increase Colorectal Cancer Screening Trial. *Cancer Epidemiol Biomarkers Prev.* 2014 Aug;23(8):1683-8.
47. Murphy CC, Vernon SW, Haddock NM, Anderson ML, **Chubak J**, Green BB. Longitudinal predictors of colorectal cancer screening among participants in a randomized controlled trial. *Preventive Medicine.* 2014 Sep;66:123-30.
48. Andersen MR, Thorpe J, Buist DSM, Beatty JD, Watabayashi K, Hanson N, Resta R, **Chubak J**, Urban N. Cancer risk awareness and concern among women with a family history of breast or ovarian cancer. *Behavioral Medicine.* 2014 Jul;25:1-11.
49. Green BB, Wang CY, Vernon SW, **Chubak J**, Meenan RT, Fuller S. Results of nurse navigator follow-up after positive colorectal cancer screening test: a randomized trial. *Journal of the American Board of Family Medicine.* 2014 Nov-Dec;27(6):789-795.
50. Hubbard RA, **Chubak J**, Rutter CM. Estimating screening test utilization using electronic health records data. *eGEMS (Generating Evidence & Methods to improve patient outcomes).* 2014 Vol. 2: Iss. 1, Article 14.
51. **Chubak J**, Hubbard RA, Johnson E, Kamineni A, Rutter CM. Assessing the effectiveness of a screening test for cancer in the presence of another screening modality in nonrandomized studies. *Journal of Medical Screening.* 2015;22(2):69-75.
52. Meenan RT, Anderson ML, **Chubak J**, Vernon SW, Fuller S, Wang C-Y, Green BB. An economic evaluation of colorectal cancer screening in primary care practice. *American Journal of Preventive Medicine.* 2015 June;48(6):714-721.
53. **Chubak J**, Onega T, Zhu W, Buist DSM, Hubbard RA. An electronic health record-based algorithm to ascertain the date of second breast cancer events. *Medical Care.* 2015 Apr 10. [Epub ahead of print].
54. Ludman EJ, McCorkle R, Bowles EA, Rutter CM, **Chubak J**, Tuzzio L, Jones S, Reid RJ, Penfold R, Wagner EH. Do depressed newly diagnosed cancer patients differentially benefit from nurse navigation? *General Hospital Psychiatry.* 2015 May-Jun;37(3):236-9.
55. Adams KF, Johnson EA, **Chubak J**, Kamineni A, Doubeni CA, Buist DSM, Williams AE, Weinmann S, Doria-Rose VP, Rutter CM. Development of an algorithm to classify colonoscopy indication from coded care plan data. *eGEMS (Generating Evidence & Methods to improve patient outcomes).* 2015 Vol 3: Iss. 1, Article 11.
56. Jones SMW, Ziebell R, Walker R, Nekhlyudov L, Rabin BA, Nutt S, Fujii M, **Chubak J**. Psychometric investigation of benefit finding among long-term cancer survivors using the Medical Expenditure Panel Survey. *European Journal of Oncology Nursing.* 2015 Jul 25. doi:10.1016/j.ejon.2015.07.005. [Epub ahead of print].

Other peer-reviewed scholarly publications

1. **Chubak J**. What can epidemiology contribute to comparative effectiveness research (CER)? *Journal of Epidemiology & Community Health.* 2013;67(3):206-207.

2. **Chubak J**, Yu O, Buist SM, Wirtz HS, Boudreau DM. Time Scales in Epidemiologic Follow-up Studies: Extending Considerations to Studies of Disease Prognosis. *Epidemiology*. 2013;24(4):628-9.

Other non-peer-reviewed scholarly publications

1. Robey T, Benki S, Mitchell B, Roberts M, **Chubak J**, FOSEP- A Model Student-led Group Linking Science and Society. *Journal of the Federation of American Scientists*. 2005 Winter:13-14.
2. Ulrich CM, **Chubak J**, McTiernan A. Re: Exercise, vitamins and respiratory tract infections. *American Journal of Medicine*. 2007 Dec;120(12):e19.
3. Hudson SV, **Chubak J**, Coups EJ, Blake-Gumbs L, Jacobsen PB, Neugut AI, Buist DSM. Identifying key questions to advance research and practice in cancer survivorship follow-up care: a report from the ASPO survivorship interest group. *Cancer Epidemiol Biomarkers Prev*. 2009 Jul;18(7):2152-4.
4. Hamilton JG, Birmingham WS, Tehranifar P, Irwin ML, Klein WMP, Nebling L, **Chubak J**. Transitioning to independence and maintaining a career in the new funding climate: a report from the American Society of Preventive Oncology's Junior Members Interest Group. *Cancer Epidemiol Biomarkers Prev*. 2013 Nov;22(11):2138-42.
5. Carrell D, Halgrim S, Tran D-T, Buist DSM, **Chubak J**, Chapman WW, Savova GK. Carrell et al. Respond to "Observational Research and the EHR." *American Journal of Epidemiology*. 2014 Mar;179(6):762-3.

Submitted manuscripts under review

1. Hubbard RA, Johnson E, **Chubak J**, Wernli K, Kamineni A, Rutter CM. Estimating screening test effectiveness when screening indication is unknown using generalized linear finite mixture models.
2. **Chubak J** and Hawkes R. Animal-assisted activities in pediatric oncology: results from a survey of top-ranked pediatric oncology hospitals.
3. Shortreed SM, Johnson EJ, Rutter CM, Kamineni A, **Chubak J**. Cohort restriction based on prior enrollment: examining potential biases in estimating cancer risk.
4. Kroenke CH, **Chubak J**, Castillo A, Weltzien E, Caan BJ. Enhancing the utility of breast cancer recurrence algorithms through selective use of medical record data.
5. Jones SMW, Ziebell R, Walker R, Nekhlyudov L, Rabin BA, Nutt S, Fujii M, **Chubak J**. Worry about cancer and benefit-finding among long-term survivors of cancer.
6. Singal AG, Tiro J, Li X, Adams-Huet B, **Chubak J**. Factors associated with hepatocellular carcinoma surveillance rates among patients with cirrhosis in a population-based integrated healthcare delivery system.
7. **Chubak J**, Garcia MP, Burnett-Hartman A, Zheng Y, Corley DA, Halm EA, Singal AG, Klabunde CN, Doubeni CA, Kamineni A, Levin TR, Schottinger JE, Green BB, Quinn VP, Rutter CR. Time to colonoscopy after positive fecal blood test in four U.S. healthcare systems.
8. Klabunde CN, Zheng Y, Quinn VP, Beaber EF, Rutter CM, Halm EA, Chubak J, Doubeni CA, Haas JS, Kamineni A, Schapira M, Vacek PM, Garcia MP, Corley DA. Influence of age and comorbidity on completion of colorectal cancer screening in the elderly.
9. **Chubak J**, Bowles EJA, Yu O, Buist DSM, Fujii M, Boudreau DM. Breast cancer recurrence in relation in antidepressant use..

10. Hubbard RA, Ripping TM, **Chubak J**, Broeders MJM, Miglioretti DL. Statistical methods for estimating the cumulative risk of screening mammography outcomes.
11. Chubak J and Hubbard RA. Defining and measuring adherence to cancer screening guidelines.
12. Nekhlyudov L, Walker R, Ziebell R, Rabin B, Nutt S, **Chubak J**. Cancer survivors' experiences with insurance, finances, and employment: results from a multi-site study.
13. Drescher CW, Beatty D, Resta R, Andersen MR, Watabayashi K, Thorpe J, Purkey H, Chubak J, Hanson N, Buist DSM, Urban N. Systematic identification of high risk women for genetic counseling and surgical prevention of ovarian cancer.

*Mentored

PATENTS AND OTHER INTELLECTUAL PROPERTY

Not applicable

FUNDING HISTORY

Completed projects

1. Trainee: Cancer Epidemiology and Biostatistics Training Grant, 2003-2006 (Principal Investigator: Noel S. Weiss). T32CA09168 funded by the National Cancer Institute.
2. Analyst (15% effort): Medications and Colorectal Cancer Risk, 8/1/2004-7/31/2008 (Principal Investigator: Denise Boudreau). 5R03CA110851-02 funded by the National Cancer Institute. Total direct costs \$100,000.
3. Co-investigator (10% effort, 1 year): Institutional and Clinical Translational Science Award, 9/17/2007-5/31/2012 (Principal Investigator: Nora Dsis). 5UL1RR025014 funded by National Institutes of Health. Group Health direct costs: \$1,319,532.
4. Co-investigator (10% effort): Center for Health Studies Value Metrics Program, 1/1/2008-12/31/2008 (Principal Investigator: Paul Fishman). Funded by Group Health Center for Health Studies. Total direct costs: \$226,591.
5. Principal Investigator (15% effort): Organization of Cancer Survivorship Care in Community-based Delivery Systems, 1/1/2009-12/31/2009. Funded by Group Health Center for Health Studies. Total direct costs: \$51,575.
6. Co-investigator (10% effort): Web-Based, Patient-Centered Approach to CVD Risk-Factor Management and Reduction, 9/30/2006-6/30/2011 (Principal Investigator: Jeffery Henderson). 5U01HL087422 funded by the National Heart, Lung, and Blood Institute. Group Health direct costs: \$66,569.
7. Principal Investigator (5% effort): Medicare Advantage SNP Evaluation, 12/1/2007-6/30/2011. Funded by Group Health Research Institute. Total direct costs: \$367,707.
8. Principal Investigator (15% effort): Cognitive Function and Breast Cancer Care. Pilot study funded by Northwest Roybal Center: Improving Healthcare for Cognitively Impaired Elders and Their Caregivers, 9/30/2009-8/31/2011 (Principal Investigator: Linda Teri, University of Washington). 1P30AG0345592 funded by the National Institute on Aging. Total direct costs of pilot: \$66,569.

9. Co-investigator (2% effort): Prevention of Ovarian Cancer in Women Participating in Mammography, 9/30/2007-9/29/2011 (Principal Investigator: Nicole Urban) 5R18DP001142 funded by the Centers for Disease Control and Prevention. Group Health direct costs: \$78,125.
10. Co-investigator (effort contributed): Feasibility study of pre-invasive HPV-related anogenital neoplasia surveillance in western Washington state, 10/1/2008-12/31/2011 (Principal Investigator: Stephen Schwartz) funded by Merck. Group Health direct costs: \$37,910.
11. Co-investigator (effort contributed): Natural Language Processing for Cancer Research Network Surveillance Studies, 9/30/2009-8/31/2011 (Principal Investigator: David Carrell). RC1CA146917 funded by the National Cancer Institute. Total direct costs: \$688,161.
12. Principal Investigator (20% effort): Algorithms to Identify Second Breast Cancer Events from Electronic Data, 1/04/2010-12/31/2011. R21CA143242 funded by the National Cancer Institute. Total direct costs: \$270,259.
13. Principal Investigator (5% effort): Risk of non-Hodgkin's Lymphoma in Relation to Tricyclic Antidepressant Use, 9/01/2011-8/31/2012: R03CA156357 funded by the National Cancer Institute. Total direct costs: \$50,000.
14. Co-investigator (5% effort): Cancer Research Network Across Health Care Systems – Infrastructure, 5/1/2007-4/30/2012 (Principal Investigator: Ed Wagner) 2U19CA079689 funded by the National Cancer Institute. Total direct costs: \$15,362,544.
15. Co-investigator (10% effort). Systems of support (SOS) to Increase Colorectal Cancer Screening and Follow-up (Principal Investigator: Beverly B. Green), 7/1/2007-5/31/2013. R01CA121125 funded by the National Cancer Institute. Total direct costs: 2,301,470.
16. Co-investigator (5% effort): Short and Long-Term Effects of a Positive CRCS Test and Longitudinal Survival Analysis of CRCS Screening Rates - Administrative Supplement, 8/1/2009-7/31/2011 (Principal Investigator: Beverly Green). 3R01CA121125-03S1 funded by the National Cancer Institute. Total direct costs: \$331,890.
17. Co-investigator and Methods Core co-lead (20% effort): SEARCH: Cancer Screening Effectiveness And Research in Community-based Healthcare, 9/30/2009-8/31/2012 (Principal Investigators: Diana Buist and Chyke Doubeni). 1UC2CA148576 funded by the National Cancer Institute. Total direct costs: \$3,619,324.
18. Co-investigator (10% effort): Commonly Used Medications and Breast Cancer Recurrence, 9/1/2007-07/31/2012 (Principal Investigator: Denise Boudreau). 1R01CA1205621 funded by the National Cancer Institute. Total direct costs \$1,141,602.
19. Co-investigator (2% effort): Commonly Used Medications and Breast Cancer Recurrence-Administrative Supplement, 9/29/2009-8/31/2012 (Principal Investigator: Denise Boudreau). R206130930 funded by the National Cancer Institute. Total direct costs: \$199,721.
20. Principal investigator (15% effort): Relationship between health care and health status in people with Type 1 diabetes, 1/1/2012-3/31/2013. Funded by Group Health Research Institute Development Fund. Total direct costs: \$100,849.
21. Site Principal Investigator (5% effort): LiveSTRONG 2012 Cancer Survivorship Survey: Collaboration with the HMO Cancer Research Network, 12/12/2012-10/31/2014. Funded by LiveSTRONG Foundation (Principal Investigator: Larissa Nekhlyudov). Total Group Health direct costs: \$76,973.

Funded projects

1. Principal Investigator (35% effort): Commonly Used Medications and Colorectal Cancer Recurrence, 9/19-2013-7/31/2017. R01CA172973 funded by the National Cancer Institute. Total direct costs: \$1,562,771.
2. Co-investigator, Site Principal Investigator, Informatics Core co-lead) (20% effort): CRN4: Cancer Research Resources & Collaboration in Integrated Health Care Systems, 9/25/2012-8/31/2017 (Principal Investigator: Larry Kushi). 1U24CA171524 funded by the National Cancer Institute. Group Health direct costs: \$1,607,111.
3. Site Principal Investigator (15% effort): A Cohort Study of Sessile Serrated Polyps and Subsequent Colorectal Neoplasia, 4/22/2013-3/31/2017 (Principal Investigator: Polly Newcomb). R01CA168338 funded by the National Cancer Institute. Group Health direct costs: \$772,199.
4. Co-investigator (2% effort). Competitive Revision: Systems of support (SOS) to Increase Colorectal Cancer Screening and Follow-up (Principal Investigator: Beverly B. Green), 9/1/2013-6/30/2018. R01CA121125 funded by the National Cancer Institute. Total direct costs: 2,314,253.
5. Co-investigator (2% effort): Testing an Optimal Model of Patient-Centered Cancer Care: CRN Clinical Communication Research Center, 9/30/2008-8/31/2014 (Principal Investigator: James Dearing). 1P20CA137219 funded by the National Cancer Institute. Group Health direct costs: \$1,022,474.
6. Principal investigator and Project 2 Lead (30% effort): SuCCESS: Studying Colorectal Cancer: Effectiveness of Screening Strategies, 9/1/2011-8/31/2016. U54CA163261 funded by the National Cancer Institute. Total direct costs: \$3,416,476.
7. Co-investigator (15% effort): Comparative Effectiveness of Preoperative Breast MRI on Surgery and Outcomes, 9/1/2011-7/31/2016 (Principal Investigator: Tracy Onega). R01CA149365 funded by the National Cancer Institute. Group Health direct costs: \$616,368.
8. Lead Investigator (20% effort): Evidence-Based Practice Center Task Order #2, 2/1/2013-11/30/2014. Funded by Agency for Healthcare Research and Quality contract to Evelyn Whitlock. Group Health direct costs: \$218,924.
9. Principal Investigator (9% effort): Developing Trials of Animal-Assisted Activities for Youth with Cancer, 4/1/2013-3/31/2015. 1R03CA169573-01A1 funded by the National Cancer Institute. Total direct costs: \$91,535.
10. Principal Investigator (concurrent effort). Positioning the PORPOISE Study for R01 funding, 1/1/2014-12/13/2014. Funded by Group Health Research Institute Development Fund. Total direct costs: \$30,434
11. Co-investigator (10%): Statistical Methods for Estimation of Benefits & Harms of Repeat Cancer Screening, 1/1/2014-12/31/2015 (Principal Investigator: Rebecca Hubbard). R03CA182986 funded by the National Cancer Institute. Total direct costs: \$100,000.

CONFERENCES AND SYMPOSIA

Organization

1. Co-organizer, public forum. "Stem Cells: The Science, The Policy, Possibilities." University of Washington. Seattle, Washington, 2004.

2. Planning committee member, School of Public Health and Community Medicine's 2nd Annual Symposium on Teaching and Learning. University of Washington, Seattle, Washington, 2005.
3. Co-organizer, symposium. "Scientists, the Public, and Policy-makers in Dialogue: Principles and Applications." American Association for the Advancement of Science. St. Louis, Missouri, 2006.
4. Co-chair, Survivorship Special Interest Group breakfast session. "Identifying key questions to advance research and practice in cancer survivorship follow-up care." American Society of Preventive Oncology. Tampa, Florida, 2009.
5. Chair, spotlight session. "Opportunities and Challenges in Studying Outcomes of Cancer." Society for Epidemiologic Research. Seattle, Washington, 2010.
6. Planning committee member, career development session. "Careers in cancer prevention: what you may not see from inside your academic department." American Society of Preventive Oncology. Washington DC, 2012.
7. Co-chair. "Cancer II – Cancer Research Network." HMO Research Network Meeting. Seattle, Washington, 2012.
8. Co-chair. "Breast Cancer: Risk Prediction, Screening, and Behavior Modification." American Society of Preventive Oncology. Washington DC, 2012.
9. Chair, career development session. "Transitioning to independence and maintaining a research career in the new funding climate." American Society of Preventive Oncology Memphis, Tennessee, 2013.
10. Scientific Planning Committee member, International Cancer Screening Network meeting, Rotterdam, the Netherlands, 2015.
11. Co-organizer and moderator. "Individualized screening." International Cancer Screening Network meeting, Rotterdam, the Netherlands, 2015.
12. Co-chair, symposium. "Epidemiology and implementation science: Designing and conducting research with the real world in mind." Society for Epidemiology Research, Denver, Colorado, 2015.

Contributed oral presentations

1. "Human germline genetic modification and our responsibilities to future generations." New Zealand Bioethics Conference. Dunedin, New Zealand, 2002.
2. "A student initiated grassroots effort to increase dialogue about science." American Association for the Advancement of Science. St. Louis, Missouri, 2006.
3. "Endometrial cancer risk in former users of unopposed estrogens: The influence of switching to combined estrogen-progestin therapy." Congress of Epidemiology. Seattle, Washington, 2006.
4. "Breast cancer recurrence risk in relation to antidepressant use after diagnosis" HMO Research Network Annual Meeting. Minneapolis, Minnesota, 2008.
5. "Colorectal cancer risk in relation to antidepressant use." American Society of Preventive Oncology. Tampa, Florida, 2009. *Honored as one of the top 16 abstracts submitted.*
6. "Providing care for cancer survivors in integrated delivery systems: preliminary results from an assessment of current practices and future opportunities." HMO Research Network Annual Meeting. Austin, Texas, 2010.
7. "Algorithms to identify second breast cancer events from administrative data." Society for Epidemiologic Research Annual Meeting. Minneapolis, Minnesota, 2012.

8. “Assessing the effectiveness of a cancer screening test in the presence of another screening modality.” Society for Epidemiologic Research Annual Meeting. Boston, Massachusetts, 2013.
9. “The Cancer Research Network: a platform for survivorship research.” Biennial Cancer Survivorship Research Conference. Atlanta, Georgia, 2014.

Invited oral presentations

1. “Methodological challenges in comparing the effectiveness of approaches to cancer screening.” Western North American Region of the International Biometric Society. Seattle, Washington, 2010.*
2. “Introduction to the Chronic Care Model.” Cancer Survivorship & Chronic Care Roundtable, George Washington Cancer Institute. Washington DC, 2011.*
3. “Common ground: proposed terminology for consistency in comparative effectiveness research—the case of cancer screening.” American Society of Preventive Oncology. Washington DC, 2012.*
4. “Providing Care to Cancer Survivors in Integrated Health Care Delivery Systems: Barriers, Facilitators, and Opportunities.” American Psychosocial Oncology Society 10th Annual Conference. Huntington Beach, California, 2013.*
5. “Commonly used medications and risk of colorectal cancer recurrence.” National Cancer Institute, Division of Cancer Control and Prevention, New Grantee Workshop, Rockville, Maryland, 2014.*
6. “Methodological issues in studies of cancer recurrence and mortality.” Joint Cancer Prevention/Epidemiology Seminar Series, Fred Hutchinson Cancer Research Center. Seattle, WA, 2014.*
7. “Data Improvement in the Cancer Research Network.” HMO Research Network Conference. Phoenix, Arizona, 2014.*

Meeting presentations made by preceptees

1. Lowry S. “Risk of non-Hodgkin lymphoma in relation to tricyclic antidepressant use.” American Society of Preventive Oncology. Washington DC, 2012. *Honored as one of the top 20 abstracts submitted.*
2. Lowry S. “Risk of non-Hodgkin lymphoma in relation to tricyclic antidepressant use.” American College of Epidemiology. Chicago, Illinois, 2012. *Received Doctoral Student Prize.*

Seminars

1. “Endometrial cancer risk in former users of unopposed estrogens: The influence of switching to combined estrogen-progestin therapy.” Fred Hutchinson Research Center. June 16, 2006.
2. “Determining date of death in women with breast cancer.” Breast Cancer Surveillance Scientific Meeting, Group Health Center for Health Studies. December 6, 2006.
3. “Selected methodological issues in pharmacoepidemiological studies.” Group Health Center for Health Studies. June 5, 2007.
4. “Medicare Special Needs Program Evaluation.” Group Health. January 16, 2008.
5. “Cost of false positive mammograms,” Breast Cancer Surveillance Scientific Meeting, Group Health Research Institute. June 29, 2009.
6. “Algorithms to Identify Second Breast Cancer Events from Electronic Data,” Group Health Research Institute. January 19, 2010.

7. “Fecal Occult Blood Testing - Is it FIT for large-scale population based screening? Results from a randomized trial and matched cohort study” (co-presenter) Alliance for Reducing Cancer, Northwest. December 8, 2011.
8. “Algorithms to Identify Second Breast Cancer Events from Administrative Data,” Women’s Health Initiative Survivor Cohort Committee Meeting, Fred Hutchinson Cancer Research Center. May 3, 2013.

*Invited

Poster presentations

1. Tworoger SS, **Chubak J**, Aiello EJ, Ulrich CM, Yasui Y, Janssen P, Potter J, Farin F, McTiernan A, “Association between *CYP17*, *CYP19*, and *COMT* genotypes and estrogen and SHBG concentrations in postmenopausal women.” American Association for Cancer Research. Washington DC, 2003.
2. Mitchell B, Roberts M, Benki S, **Chubak J**, Robey T. “The Forum on Science Ethics and Policy: A new Seattle organization stimulates discussion on the role of science in our society.” American Association for the Advancement of Science. Washington DC, 2005.
3. **Chubak J**, Tworoger SS, Yasui Y, Ulrich CM, Stanczyk FZ, McTiernan A. “Associations between reproductive and menstrual factors and postmenopausal androgen concentrations.” American Association for Cancer Research. Anaheim, California, 2005.
4. Tworoger SS, Sorensen B, **Chubak J**, McTiernan A. “The effect of a 12-month randomized controlled trial of exercise on serum prolactin concentrations in postmenopausal women.” Congress of Epidemiology. Seattle, Washington, 2006.
5. Hawkins V, **Chubak J**, Sorensen B, Stanford J, White E, McTiernan A. “Influence of exercise on serum sex hormones in men: a 12-month randomized controlled clinical trial.” congress of Epidemiology. Seattle, Washington, 2006.
6. **Chubak J**, Buist DSM, Boudreau DM, McKnight B, Rossing MA, Weiss NS. “Approaches to reducing confounding by indication in a study of breast cancer prognosis in relation to the use of antidepressants after diagnosis.” International Congress of Pharmacoepidemiology. Lisbon, Portugal, 2006.
7. Tuzzio L, **Chubak J**, Hsu C, Kirlin B, Nekhlyudov L, for the CRN Survivorship Scientific Interest Group. “Providing care for cancer survivors in integrated delivery systems: an assessment of current practices and future opportunities.” AcademyHealth. Boston, Massachusetts, 2010.
8. **Chubak J**, Hsu C, Tuzzio L, Kirlin B, Nekhlyudov L, for the CRN Survivorship Scientific Interest Group. “Providing care for cancer survivors in integrated delivery systems: an assessment of current practices and future opportunities.” Fifth Biennial Cancer Survivorship Research Conference. Washington DC, 2010.
9. Bowles EJA, Buist DSM, **Chubak J**, Yu O, Boudreau DM. “Uptake of tamoxifen and aromatase inhibitors in women with early stage, invasive breast cancer in a community setting, 2001-2008.” American Society of Preventive Oncology. Las Vegas, Nevada, 2011.
10. Pocobelli G, **Chubak J**, Buist D, Hanson N, Drescher C, Resta R, and Urban N. “Rates of prophylactic oophorectomy before and after the introduction of a clinical practice guideline on the referral of high-risk women to genetic counseling.” American Society of Preventive Oncology. Las Vegas, Nevada, 2011.

11. **Chubak J**, Pocobelli G, Weiss NS. “Considerations in developing and using electronic healthcare data algorithms for epidemiologic and health services research.” Congress of Epidemiology. Montreal, Canada, 2011.
12. Boudreau DM, Key D, **Chubak J**. “Comparison of different methods for calculating medication exposure.” International Congress of Pharmacoepidemiology. Chicago, Illinois, 2011.
13. **Chubak J**, Bogart A, Laing S, Green B. “Comparing uptake of fecal occult blood tests for colorectal cancer screening: results from a randomized controlled trial.” American Society of Preventive Oncology. Washington DC, 2012. *Poster received honorable mention.*
14. **Chubak J**, Bogart A, Laing S, Green B. “Comparing uptake of fecal occult blood tests for colorectal cancer screening: results from a randomized controlled trial.” International Cancer Screening Network. Sydney, Australia, 2012.
15. **Chubak J**, Hubbard R, Kamineni A, Wernli K, Rutter R. “Defining and calculating measures of screening participation for international comparative effectiveness research.” International Cancer Screening Network. Sydney, Australia, 2012.
16. **Chubak J**, Rutter CM, Kamineni A, Johnson EA, Stout NK, Weiss NS, Doria-Rose VP, Doubeni CA, Buist DSM. “Relative effectiveness measures: defining and understanding the essential features for comparative effectiveness research.” International Cancer Screening Network. Sydney, Australia, 2012.
17. **Chubak J** and Flaherty L. “Oncology Nurse Navigator Trial.” Group Health Research Rounding. Seattle, Washington, 2013.
18. Ludman E, Bowles E, Rutter C, **Chubak J**, Penfold R, Reid R, McCorkle R, Wagner E. Newly diagnosed cancer patients with and without depressive symptoms benefit from nurse navigation. American Psychosocial Oncology Society. Tampa, Florida, 2014.
19. Burnett-Hartman AN, **Chubak J**, Kamineni A, Ziebell R, Upton MP, Zhu L-C, Newcomb A. Short-term risk of colorectal cancer in colonoscopy patients with sessile serrated polyps.” American Society of Preventive Oncology. Arlington, Virginia, 2014.
20. **Chubak J**, Ziebell R, Hart G, Greenlee R, Honda S, Hornbrook M, Lamerato L, Mazor K, Nekhlyudov L, Pawloski P, Ritzwoller D, Quinn V, Doria-Rose VP, Kushi L. “Cancer Research Network: Data availability pre- and post- cancer diagnosis.” HMO Research Network Conference. Phoenix, Arizona, 2014.
21. Halgrim SR, Sizemore L, Pham E, Gundersen G, Carrell DS, Wernli K, **Chubak J**, Rutter CM. “Linking adenomas between colonoscopy and pathology notes for PROSPR.” American Medical Informatics Association. Washington, DC, 2014.
22. Ziebell R, Hart G, Chubak J, Krajenta R, Lamerato L, Miroshnik I, Nekhlyudov L, DeFor L, Pawloski P, Tabano D, Ritzwoller D, Wong C, Schmidt M, Rust M, Hornbrook MC, Ghai N, Quinn V, McManus V, Greenlee R, Fouayzi H, Epstein M, Lee V, Kushi L. “Colorectal cancer data in the Cancer Research Network.” HMO Research Network Conference. Long Beach, California, 2015.
23. **Chubak J**, Garcia M, Burnett-Hartman A, Zheng Y, Halm EA, Corley DA, Kamineni A, Singal AG, Green BB, Doubeni CA, Klabunde CN, Rutter CM. “Factors associated with time to colonoscopy after a positive fecal occult blood test .” American Society of Preventive Oncology. Birmingham, Alabama, 2015.

24. Hubbard RA, Ripping TM, **Chubak J**, Miglioretti DM, Broeders MJM. “Accounting for censoring in estimation of cumulative risk of false-positive screening mammography results using observational data.” International Cancer Screening Network. Rotterdam, the Netherlands, 2015.
25. Wernli KJ, Hubbard RA, Johnson E, **Chubak J**, Kamineni A, Green BB, Rutter CM. “Patterns of colorectal cancer screening uptake in newly-eligible men and women.” International Cancer Screening Network. Rotterdam, the Netherlands, 2015.
26. Nekhlyudov L, Walker R, Ziebell R, Rabin B, Nutt S, **Chubak J**. “Cancer survivors’ experiences with insurance, personal finances, and employments: results from a multi-site study.” American Society of Clinical Oncology. Chicago, Illinois, 2015.

PROFESSIONALLY RELATED COMMUNITY SERVICE

Panelist, Epidemiology 584 career panel, University of Washington, 2009
 Panelist, Whitman Middle School Annual Science Fair, 2009 – 2011
 Speaker, Eckstein Middle School, Student Interest Assessment (college/career planning), 2013
 Participant, Epi Expo, University of Washington, 2014

TEACHING HISTORY

Formal courses

Tutor (Lecturer), “Patient, Doctor, and Society,” University of Otago, New Zealand, 2001 – 2002
 Teaching Assistant, “Epidemiologic Methods,” University of Washington, 2006 – 2007

Guest lecturer

Case study discussion co-leader “Research Ethics,” Fred Hutchinson Cancer Research Center, 2005
 Lecturer, “Epidemiology 101,” Group Health Center for Health Studies, 2007
 “Marginal Structural Models” lecture, University of Washington, Pharmacoepidemiology, 2008
 Session leader, Epidemiology journal club, University of Washington, 2009
 “Cancer as a chronic disease: managing care for cancer survivors.” Oncology symposium for the primary care team, Seattle Cancer Care Alliance, 2013

ADVISING AND FORMAL MENTORING

PhD committees in non-chair roles

Member, Doctoral Committee for Sarah Lowry, Department of Epidemiology, University of Washington, 2009 – 2012
 Member, Doctoral Committee for Lu Chen, Department of Epidemiology, University of Washington, 2014 – present

Academic advising

Research Assistant Supervisor, Gaia Pocobelli, MSc; PhD student in Epidemiology, University of Washington, School of Public Health, 2009 – 2011
 Student Intern Supervisor, David Liss, MA, PhD student in Health Services, University of Washington, School of Public Health, 2009 – 2010

Other mentoring

Research Associate Supervisor, Dr. Aruna Kamineni, Group Health Research Institute, 2009 – 2012
 Cancer Research Network (CRN) Scholars mentoring committee member:

Dr. Dori Rosenberg, PhD, Group Health Research Institute, 2013 – present
Dr. Amit Singal, MD, MPH, University of Texas Southwestern, 2013 – present
Dr. Kim Danforth, PhD, Kaiser Permanente Southern California, 2015 – present
Dr. Salene M.W. Jones, PhD, Group Health Research Institute, 2014 – 2015

OTHER PERTINENT INFORMATION

Coordinator, Cancer Researchers Group, Group Health Research Institute, 2007 – 2010
Abstract reviewer, 2012 HMO Research Network Annual Meeting, 2011
Abstract reviewer, 2012 American Society of Preventive Oncology Annual Meeting, 2011
Abstract reviewer, 2013 Society for Epidemiologic Research Annual Meeting, 2013
Abstract reviewer, 2015 International Cancer Screening Network meeting